Long-term effect of a single dose of flunarizine in Huntington's disease

European Journal of Neurology

Volumn 5, Issue 3, 1998, Pages 249-253

  Belfiore, G ^a   Di Maio, L ^b   Napolitano, G ^b   Cella, S ^b   Filla, A ^b   De Michele, G ^b   Campanella, G ^b,c  

^a VITO FAZZI HOSPITAL   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c IRCCS NEUROMED   (Italy)

Author keywords

Flunarizine therapy; Huntington's disease

Indexed keywords

CALCIUM ANTAGONIST; FLUNARIZINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HUNTINGTON CHOREA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; SUBLINGUAL DRUG ADMINISTRATION;

EID: 0031832671     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.1998.530249.x     Document Type: Article

References (18)

1. Andermann F, Ohtahara S, Andermann E, Camfield P, Kobayashi K (1994). Infantile hypotonia and paroxysmal dystonia: a variant of alternating hemiplegia of childhood? Movement Disorders 9:227-229.
2. Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, Stan E, Squitieri F, Lin B, Kalchman MA, Graham RK, Hayden MR (1993). The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nature Genet 4:398-403.
3. Ashton D, Marrannes R, Pauwels PJ, Van-Belle H, Reid K, Wauquier A (1985). Possible mechanisms of flunarizine's anticonvulsant activity. Proceedings of the International Workshop on "Flunarizine in Epilepsy", Beerse, Belgium.
4. Bonuso S, Di Stasio E, Marano E, Sorge F, Leo A (1986). Sublingual flunarizine: a new effective management of the migraine attack. A comparison versus ergotamine. Headache 26:227-230.
5. Brucke T, Wober C, Podreka I, Wober-Bingol C, Asenbaum S, Aull S, Wengen S, Ilieva D, Harasko van der Meer C, Wessely P (1995). D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study. J Cerebral Blood Flow Metab 15:513-518.
6. Chouza C, Scaramelli A, Caamano JL, De Medina O, Alyanati R, Romero S (1986). Parkinsonism, tardive dyskinesia, acathysia and depression induced by flunarizine. Lancet II:1303-1304.
7. De Michele G, Filla A, Coppola N, Mansi D, Brescia Morra V, Buscaino GA (1987). Extrapyramidal side-effects of flunarizine. Acta Neurol 9(XLII):230-233.
8. Folstein SE, Jensen B, Leigh RJ, Folstein ML (1983). The measurement of abnormal movements: method developed for Huntington's disease. Neurobehav Toxicol Teratol 5:605-609.
9. Heykants J, Michelsen L, Lorreyne W, Woestenborghs R, Scheijgroud H and Reyntjens A (1981). Bioequivalence study of two flunarizine formulations (a 5 mg capsule and a 10mg tablet) in a group of 6 healthy subjects. Unpublished report, Janssen.
10. Holmes B, Brogden RN, Heel RC, Speight TM and Avery GS (1984). Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 27:6-44.
11. Huntington's Disease Collaborative Research Group (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-983.
12. Lou HC (1989). Flunarizine in paroxysmal choreoathetosis. Neuropediatrics 20:112.
13. Maniatis T, Fritsch EF, Sambrook J (1982). Molecular cloning. A laboratory manual. New York: Cold Spring Harbor Laboratory.
14. Micheli F, Pardal MF, Gatto M, Torres M, Paradiso G, Parera IC and Giannaula R (1987). Flunarizine- and cinnarizine-induced extrapyramidal reactions. Neurology 37:881-884.
15. Michiels M, Hendriks R, Knaeps F, Woestenborghs R, Heykants J (1983). Absorption and tissue distribution of flunarizine in rats, pigs and dogs. Arzneimittel Forsch 33:1135-1142.
16. Reid KH, Marranes R, Wauquier A (1987). Effects of flunarizine on rat cerebral cortex. Drug Devel Res 10:107-116.
17. Shoulson I (1982). Care of patients and families with Huntington's disease. In: Neurology (International Medical Review Series) Vol.2-Movement disorders. Marsden CD and Fahn S (editors). London: Butterworth Scientific. pp. 227-290.
18. Wauquier A, Ashton D, Clincke G, Fransen J, Gillardin JM, Jansen Paul AJ (1986). Anticonvulsant profile of flunarizine. Drug Devel Res 7:49-60.